WallStSmart

MiniMed Group, Inc. Common Stock (MMED)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 7% more annual revenue ($3.33B vs $3.10B). WST leads profitability with a 17.0% profit margin vs -10.7%. WST earns a higher WallStSmart Score of 61/100 (C+).

MMED

Hold

37

out of 100

Grade: F

Growth: 6.7Profit: 4.0Value: 5.0Quality: 6.8
Piotroski: 4/9

WST

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 2.7Quality: 8.5
Piotroski: 4/9Altman Z: 4.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MMED.

WSTSignificantly Overvalued (-47.9%)

Margin of Safety

-47.9%

Fair Value

$166.45

Current Price

$348.76

$182.31 premium

UndervaluedFair: $166.45Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MMED3 strengths · Avg: 9.3/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
15.6%8/10

15.6% revenue growth

WST3 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.7310/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Operating MarginProfitability
22.5%8/10

Strong operational efficiency at 22.5%

Areas to Watch

MMED4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Free Cash FlowQuality
$-226.00M2/10

Negative free cash flow — burning cash

Profit MarginProfitability
-10.7%1/10

Currently unprofitable

WST3 concerns · Avg: 2.7/10
Price/BookValuation
8.3x4/10

Trading at 8.3x book value

PEG RatioValuation
2.912/10

Expensive relative to growth rate

P/E RatioValuation
43.5x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : MMED

The strongest argument for MMED centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 15.6% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 22.5%. Revenue growth of 13.8% demonstrates continued momentum.

Bear Case : MMED

The primary concerns for MMED are EPS Growth, Return on Equity, Free Cash Flow.

Bear Case : WST

The primary concerns for WST are Price/Book, PEG Ratio, P/E Ratio. A P/E of 43.5x leaves little room for execution misses.

Key Dynamics to Monitor

MMED profiles as a growth stock while WST is a mature play — different risk/reward profiles.

MMED is growing revenue faster at 15.6% — sustainability is the question.

WST generates stronger free cash flow (81M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

WST scores higher overall (61/100 vs 37/100), backed by strong 17.0% margins and 13.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

MiniMed Group, Inc. Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Minimed Group, Inc. is a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company is headquartered in Northridge, California.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?